...
首页> 外文期刊>Cancer Treatment Reviews >PD-L1 expression and clinical outcomes in patients with advanced urothelial carcinoma treated with checkpoint inhibitors: A meta-analysis
【24h】

PD-L1 expression and clinical outcomes in patients with advanced urothelial carcinoma treated with checkpoint inhibitors: A meta-analysis

机译:检查点抑制剂治疗晚期尿路上皮癌患者的PD-L1表达及临床结果:META分析

获取原文
获取原文并翻译 | 示例
           

摘要

Context: Five checkpoint inhibitors have been approved as 1st line (cisplatin-ineligible) or 2nd line therapies for patients with metastatic urothelial carcinoma of the bladder. As only about 30% of patients respond, the need for a biomarker for patient selection exists.
机译:背景:五种检查点抑制剂已被批准为膀胱转移性尿路上皮癌患者的第一线(顺铂 - 不合格)或第二线疗法。 只有大约30%的患者的作用,存在对患者选择的生物标志物的需要。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号